A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients

Inclusion Criteria

• •FIGO stage: ⅠB～ⅡA, cervical cancer;
• •Age≤60 years; female, Chinese women;
• •Initial treatment is radical hysterectomy + pelvic lymph node dissection;
• •Pathological diagnosis: cervical squamous cell invasive carcinoma;
• •Pathologic examination and meet the following one of the indications of adjuvant therapy: ① lymph node metastasis, ② parametrial invasion, ③ ≥ 2/3 deep stromal invasion, ④ histopathological grading in poorly differentiated (G2 to G3), ⑤ lymphatic vascular space involvement, ⑥ tumor diameter\> 4cm;
• •Laboratory tests: WBC≥4×10(9)/L, NEU≥2×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal, BUN, Cr≤ normal
• •Performance status: Karnofsky score≥60;
• •No prior treatment;
• •Receiving extensive resection of uterus (type III) plus pelvic lymph nodes wide resection; pathologically diagnosed with cervical squamous cell carcinoma;
• •Provide written informed consent.